Výsledky vyhledávání - "ErbB Receptors"

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients Autor Yang, Zhe, Yang, Nong, Ou, Qiuxiang, Xiang, Yi, Jiang, Tao, Wu, Xue, Bao, Hua, Tong, Xiaoling, Wang, Xiaonan, Shao, Yang W, Liu, Yunpeng, Wang, Yan, Zhou, Caicun

“…The third-generation tyrosine kinase inhibitor osimertinib is approved to treat patients with T790M-positive non-small cell lung cancer (NSCLC) who have…”
Zjistit podrobnosti o přístupu

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism Autor Abourehab, Mohammed A. S., Alqahtani, Alaa M., Youssif, Bahaa G. M., Gouda, Ahmed M.

“…Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer therapy. Since the FDA approval of the first EGFR-TKI, erlotinib,…”
Získat plný text

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer Autor Harrison, Peter T., Vyse, Simon, Huang, Paul H.

“…Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC). Classical activating…”
Získat plný text

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer Autor Uchibori, Ken, Inase, Naohiko, Araki, Mitsugu, Kamada, Mayumi, Sato, Shigeo, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei

“…Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation…”
Získat plný text

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors Autor Jia, Yong, Yun, Cai-Hong, Park, Eunyoung, Ercan, Dalia, Manuia, Mari, Juarez, Jose, Xu, Chunxiao, Rhee, Kevin, Chen, Ting, Zhang, Haikuo, Palakurthi, Sangeetha, Jang, Jaebong, Lelais, Gerald, DiDonato, Michael, Bursulaya, Badry, Michellys, Pierre-Yves, Epple, Robert, Marsilje, Thomas H., McNeill, Matthew, Lu, Wenshuo, Harris, Jennifer, Bender, Steven, Wong, Kwok-Kin, Jänne, Pasi A., Eck, Michael J.

“…An allosteric inhibitor, EAI045, is reported that is selective for certain drug-resistant EGFR mutants, but spares the wild-type receptor; combination therapy…”
Získat plný text

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors Autor Amelia, Tasia, Kartasasmita, Rahmana Emran, Ohwada, Tomohiko, Tjahjono, Daryono Hadi

“…Lung cancer has a high prevalence, with a growing number of new cases and mortality every year. Furthermore, the survival rate of patients with non-small-cell…”
Získat plný text

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma Autor Choi, Bryan D., Gerstner, Elizabeth R., Frigault, Matthew J., Leick, Mark B., Mount, Christopher W., Balaj, Leonora, Nikiforow, Sarah, Carter, Bob S., Curry, William T., Gallagher, Kathleen, Maus, Marcela V.

“…In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which…”
Získat plný text

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells Autor Taniguchi, Hirokazu, Yamada, Tadaaki, Wang, Rong, Tanimura, Keiko, Adachi, Yuta, Nishiyama, Akihiro, Tanimoto, Azusa, Takeuchi, Shinji, Araujo, Luiz H., Boroni, Mariana, Yoshimura, Akihiro, Shiotsu, Shinsuke, Matsumoto, Isao, Watanabe, Satoshi, Kikuchi, Toshiaki, Miura, Satoru, Tanaka, Hiroshi, Kitazaki, Takeshi, Yamaguchi, Hiroyuki, Mukae, Hiroshi, Uchino, Junji, Uehara, Hisanori, Takayama, Koichi, Yano, Seiji

“…A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR -mutated lung cancer. However, some patients show…”
Získat plný text

Production and functional analysis of a phage displayed scFv recombinant antibody targeting EGFR/HER2 dimerization domain Autor Dabiri, Mina, Tehrani, Mohsen, Rafiei, Alireza, Valadan, Reza

“…Tumor cells exploit epidermal growth factor receptor (EGFR) family to develop resistance against therapeutic antibodies, such as Herceptin. Upon ligand…”
Získat plný text

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment Autor Haratani, K, Hayashi, H, Tanaka, T, Kaneda, H, Togashi, Y, Sakai, K, Hayashi, K, Tomida, S, Chiba, Y, Yonesaka, K, Nonagase, Y, Takahama, T, Tanizaki, J, Tanaka, K, Yoshida, T, Tanimura, K, Takeda, M, Yoshioka, H, Ishida, T, Mitsudomi, T, Nishio, K, Nakagawa, K

“…The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with…”
Zjistit podrobnosti o přístupu

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer Autor Cho, Byoung Chul, Felip, Enriqueta, Hayashi, Hidetoshi, Thomas, Michael, Lu, Shun, Besse, Benjamin, Sun, Tao, Martinez, Melissa, Sethi, Seema N, Shreeve, S Martin, Spira, Alexander I

“…Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer;…”
Zjistit podrobnosti o přístupu

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development Autor Binder, Zev A, Thorne, Amy Haseley, Bakas, Spyridon, Wileyto, E Paul, Bilello, Michel, Akbari, Hamed, Rathore, Saima, Ha, Sung Min, Zhang, Logan, Ferguson, Cole J, Dahiya, Sonika, Bi, Wenya Linda, Reardon, David A, Idbaih, Ahmed, Felsberg, Joerg, Hentschel, Bettina, Weller, Michael, Bagley, Stephen J, Morrissette, Jennifer J D, Nasrallah, MacLean P, Ma, Jianhui, Zanca, Ciro, Scott, Andrew M, Orellana, Laura, Davatzikos, Christos, Furnari, Frank B, O'Rourke, Donald M

“…We explored the clinical and pathological impact of epidermal growth factor receptor (EGFR) extracellular domain missense mutations. Retrospective assessment…”
Zjistit podrobnosti o přístupu

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer Autor Passaro, A, Leighl, N, Blackhall, F, Popat, S, Kerr, K, Ahn, M J, Arcila, M E, Arrieta, O, Planchard, D, de Marinis, F, Dingemans, A M, Dziadziuszko, R, Faivre-Finn, C, Feldman, J, Felip, E, Curigliano, G, Herbst, R, Jänne, P A, John, T, Mitsudomi, T, Mok, T, Normanno, N, Paz-Ares, L, Ramalingam, S, Sequist, L, Vansteenkiste, J, Wistuba, I I, Wolf, J, Wu, Y L, Yang, S R, Yang, J C H, Yatabe, Y, Pentheroudakis, G, Peters, S

“…The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell…”
Zjistit podrobnosti o přístupu

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study Autor Hainsworth, John D, Meric-Bernstam, Funda, Swanton, Charles, Hurwitz, Herbert, Spigel, David R, Sweeney, Christopher, Burris, Howard, Bose, Ron, Yoo, Bongin, Stein, Alisha, Beattie, Mary, Kurzrock, Razelle

“…Purpose Detection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer…”
Zjistit podrobnosti o přístupu

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer Autor Leonetti, Alessandro, Sharma, Sugandhi, Minari, Roberta, Perego, Paola, Giovannetti, Elisa, Tiseo, Marcello

“…Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-…”
Získat plný text

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study Autor Goss, Glenwood, Tsai, Chun-Ming, Shepherd, Frances A, Bazhenova, Lyudmila, Lee, Jong Seok, Chang, Gee-Chen, Crino, Lucio, Satouchi, Miyako, Chu, Quincy, Hida, Toyoaki, Han, Ji-Youn, Juan, Oscar, Dunphy, Frank, Nishio, Makoto, Kang, Jin-Hyoung, Majem, Margarita, Mann, Helen, Cantarini, Mireille, Ghiorghiu, Serban, Mitsudomi, Tetsuya

“…Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and…”
Získat plný text

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics Autor Arteaga, Carlos L, Engelman, Jeffrey A

“…ERBB receptors were linked to human cancer pathogenesis approximately three decades ago. Biomedical investigators have since developed substantial…”
Zjistit podrobnosti o přístupu

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors Autor Sabbah, Dima A, Hajjo, Rima, Sweidan, Kamal

“…The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase receptors. EGFR signaling cascade is a key regulator in cell…”
Zjistit podrobnosti o přístupu

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer Autor Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Zjistit podrobnosti o přístupu

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Autor Park, Keunchil, Haura, Eric B, Leighl, Natasha B, Mitchell, Paul, Shu, Catherine A, Girard, Nicolas, Viteri, Santiago, Han, Ji-Youn, Kim, Sang-We, Lee, Chee Khoon, Sabari, Joshua K, Spira, Alexander I, Yang, Tsung-Ying, Kim, Dong-Wan, Lee, Ki Hyeong, Sanborn, Rachel E, Trigo, José, Goto, Koichi, Lee, Jong-Seok, Yang, James Chih-Hsin, Govindan, Ramaswamy, Bauml, Joshua M, Garrido, Pilar, Krebs, Matthew G, Reckamp, Karen L, Xie, John, Curtin, Joshua C, Haddish-Berhane, Nahor, Roshak, Amy, Millington, Dawn, Lorenzini, Patricia, Thayu, Meena, Knoblauch, Roland E, Cho, Byoung Chul

“…Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved…”
Zjistit podrobnosti o přístupu